Friday, 5th October Australasian Melanoma Conference 2018

• Epidemiological Trends in Melanoma - David Whiteman

• Insights into melanocyte development - David Erich Fisher
• Host pigmentation factors and genotype analysis of high risk melanoma patients - Richard Sturm
• Dissection of melanocytic subpopulations - Fumihito Noguchi

• Artificial intelligence - The new frontier in melanoma diagnosis - Justin Ko
• Early diagnosis using telemedicine and technology - Peter Soyer

9:55 AM Panel Discussion

• Germline predictors of melanoma development - Nick Hayward
• Different genetic mechanisms mediate spontaneous versus UVR-induced malignant melanoma - Graeme Walker
• Incidence of melanoma in commercial pilots in Australia - Catherine M Olsen
• Melanin pigment and melanoma heterogeneity - Gamze Kuser Abali
• Origin of vascular progenitors driving melanoma angiogenesis in vivo - Kiarash Khosrotehrani

• Overdiagnosis in melanoma - how big is the problem? - David Whiteman
• Biopsy - controversies and developments - John Kelly
• The truth about sun protection and Vitamin D - Rachel Neale
• Borderline Lesions: histological and management challenges - Richard Scolyer

12:25 PM Discussion

• Melanoma: clues to therapeutic efficacy from disease pathogenesis - David Erich Fisher

• Insights from the Australian Melanoma Genome Project - Graham Mann
• Pattens of evolution found in lethal melanomas stratify patient survival - Tony Papenfuss
• Immunogenomic and bioinformatic approaches to predict immunogenicity - Nic Waddell

• Sentinel Node Biopsy when should it be done - Mark Smithers
• Sentinel Node Biopsy when it should not be done - Michael Henderson
• Management of the Positive Sentinel Node Biopsy - David Gyorki
• Challenges of special subtypes of melanoma - ALM, desmoplastic, neurotropic, extensive LM  - Michael Henderson

3:10 PM Panel Discussion

• Small molecule inhibitors of melanoma: from fungal creams to microRNAs - Peter Leedman
• Less is more: subclinical doses and choice of replication stress inducer in combination with CHK1 inhibitors in vitro and in vivo - Brian Gabrielli
• Overcoming therapy induced reprogramming of metabolism in BRAF^V600 melanoma - Lorey K Smith
• Dynamic regulation of melanoma cell proliferation and therapy resistance - Nikolas Haass
• OGT-mediated cellular reprogramming drives MAPKi-induced drug resistance - Helmut Schaider

• Loco-regional strategies for local recurrence and in transit metastasis - Jonathan Zager
• Approaches to extensive regional nodal involvement - Andrew Spillane
• Is there any role for Radiotherapy for loco-regional recurrence - Vanessa Estall
• Systemic therapies for loco-regional metastases - Alexander Menzies

• An approach to dermoscopy in clinical practice  - Cliff Rosendahl
• Dermoscopic diagnosis of melanoma - Marius Rademaker
• How to distinguish benign imitators of melanoma with dermoscopy - Caterina Longo
• Interactive Dermoscopy Quiz - Yan Pan

• Protein glycosylation features of metastatic melanoma: the search for prognostic markers - Jodie L Abrahams
• A randomised trial of excision margins for melanoma (ANZMTG 03.12 MelMarT) - Evan Buck
• Quality assurance of the ANZMTG 01.07 TROG 08.05 WBRTMel whole brain radiotherapy in melanoma randomised trial - Gerald B Fogarty
• Effect of a previous diagnosis of primary invasive melanoma on the progression of subsequent primary invasive melanoma - Sharene Chong
• Antibody profiling to predict responses to immunotherapy in melanoma - Jessica Da Gama Duarte
• Novel sources of peptide antigens in the melanoma immunopeptidome - Pouya Faridi
• The presence of CXCR6 on CD8+ T cells a biomarker for poor treatment outcomes in metastatic melanoma patients on Pembrolizumab? - Moira Graves
• Clinical Application of Circulating Tumour Cells and Circulating Tumour DNA in Uveal Melanoma   - Elin Gray
• A novel murine model to study lymph node metastases - Katharina Hochheiser
• Nodular melanoma: analysis of prognostic factors, anatomical site and patient characteristics - Matthew D Howard
• Desmoplastic melanoma: anatomical site and other prognostic factors - Matthew Howard
• Survivorship issues in patients with metastatic melanoma on long-term immune checkpoint and BRAF and MEK inhibitors: analysis of survey free-text - Julia Lai-Kwon
• A novel immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapy - Emily Lelliott
• Cosmetic nail treatment with nail ultraviolet lamp and melanoma: Review of the risk. - Arthur Martin
• Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients   - Ashleigh C McEvoy
• The evolving management of in-transit melanoma metastases at a high volume centre. - Emilia Nan Tie
• AXMAP – the Australian pdX MelanomA Project - Angela Peng
• The role of KDM6A in melanoma - Gaya Punnia-Moorthy
• Establishment of a biospecimen resource to evaluate treatment response and outcome in Merkel cell carcinoma - Jeanette Raleigh
• Symptom status does not impact long-term survival when melanoma brain metastasis receive upfront stereotactic radiotherapy - Gishan Ratnayake
• General practitioner expectations and attitudes towards communicating personal melanoma genomic risk information to the public - Amelia K Smit
• Whole-exome sequencing of acquired naevi identifies mechanisms for development and maintenance of benign neoplasms - Mitchell S Stark
• Investigating Dabrafenib plus Trametinib-induced pyrexia – An unsolved clinical problem - Cindy Hsin-Yi Tseng
• A Plasma MicroRNA Biomarker of Melanoma as a Personalised Assessment of Treatment Response. - Ryan Van Laar
• The control of melanoma metastasis by the YAP oncogene - Lie Yang
• Primary dermal melanoma - a description of a patient cohort at an Australian tertiary centre  - Louise Photiou

A course on the role of confocal microscopy in melanoma diagnosis and management